Foresight Nanotech Institute Logo
Image of nano

Nanotechnology shrinks tumors by targeting two genes

One of the advantages of nanotech treatments for cancer is that nanoparticles can be large enough to introduce more than one type of therapeutic molecule into the same cancer cell. Another advantage is that nanoparticles can protect and deliver into cells molecules that would never make it into the cancer cell unassisted. Now scientists at Pennsylvania State University have demonstrated that nanoparticles can introduce two very promising, but easily degraded, therapeutic molecules into a laboratory model of human skin, and that together they are much more effective than either is alone is slowing the development of deadly melanoma skin cancer. From the National Cancer Institute’s Alliance for Nanotechnology in Cancer “Nanoparticles Target Multiple Cancer Genes, Shrink Tumors More Effectively“:

Nanoparticles filled with small interfering RNA (siRNA) molecules targeting two genes that trigger melanoma have shown that they can inhibit the development of melanoma, the most dangerous type of skin cancer. The nanoparticles, administered in conjuction with ultrasound irradiation, exerted their effects only on malignant tissue, leaving healthy tissue alone.

“It is a very selective and targeted approach,” said Gavin Robertson, Ph.D., who led the team of researchers from the Penn State College of Medicine. “And unlike most other cancer drugs that inadvertently affect a bunch of proteins, we are able to knock out single genes.”

The Penn State researchers speculated that siRNA could turn off the two cancer-causing genes and potentially treat the deadly disease more effectively. “siRNA checks the expression of the two genes, which then lowers the abnormal levels of the cancer causing proteins in cells,” explained Dr. Robertson. This research appears in the journal Cancer Research [abstract].

In recent years, researchers have zeroed in on two key genes—B-Raf and Akt3—that play key roles in the development of melanoma. Mutations in the B-Raf gene, the most frequently mutated gene in melanoma, lead to the production of a mutant form of the B-Raf protein, which then helps mole cells survive and grow. B-Raf mutations alone, however, do not trigger melanoma development. That event requires a second protein, called Akt3, that regulates the activity of the mutated B-Raf, which aids the development of melanoma. The siRNA agents used in this study specifically target Akt3 and the mutant B-Raf and therefore do not affect normal cells.

However, although knocking out specific genes may seem like a straightforward task, delivering the siRNA drug to cancerous cells is another story, because not only do protective layers in the skin keep drugs out but also chemicals in the skin quickly degrade the siRNA. To clear these two hurdles, Dr. Robertson and his team engineered lipid-based nanoparticles that can incorporate siRNA into their hollow interiors. The researchers then used a portable ultrasound device to temporarily create microscopic holes in the surface of the skin, allowing the drug-filled particles to leak into tumor cells beneath.

When the researchers exposed lab-generated skin containing early cancerous lesions to the treatment 10 days after the skin was created, the siRNA reduced the ability of cells containing the mutant B-Raf to multiply by nearly 60 to 70 percent and more than halved the size of lesions after 3 weeks. “This is essentially human skin with human melanoma cells, which provides an accurate picture of how the drug is acting,” said Dr. Robertson.

—Jim

One Response to “Nanotechnology shrinks tumors by targeting two genes”

  1. Anonymous Says:

    What an interesting article. I have long wanted to familiarize myself, as much as a layman can, with these incredible developments and am finally becoming increasingly proactive about it.

    My father in law died of skin cancer a few years ago and I wonder if he had lived today under the same conditions, whether or not he would be able to participate in this research as a volunteer.

    How far have we come in this regard?

Leave a Reply